Neurotech International reports positive preclinical data from combination study

Latest News

Neurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.

The company said that when NTI164 was coupled with diclofenac, significant anti-inflammatory synergistic action was seen at a low dose.

Lowering the diclofenac dose while increasing efficacy could alleviate many of the negative side effects that are directly tied to its dosage.

The company said the findings give it a strong foundation on which to build strategic alliances and extend its clinical portfolio. It said it will seek to accelerate commercial negotiations with potential strategic partners.

Chairman Brian Leedman said, “These preclinical results are incredibly exciting from a company development perspective. We now have both prednisone and diclofenac, two very commonly used off-patent pharmaceutical drugs for inflammatory disorders, demonstrating significant improvement in effect using up to 90 per cent less active dosage when used in combination with NTI164.

"The potential to create combination treatments with NTI164 plus Diclofenac and/or Prednisone that increases efficacy and significantly reduces side effects is now a major driver for the company. Given the impending release of our final ASD study results, the Company is well and truly positioned for an extremely busy second half to the year as we move to secure strategic partners and undertake further clinical trials given our results to date.”

Non-executive director Professor Allan Cripps added, “These preclinical findings are very encouraging as they are in line with the results we previously reported with prednisone. What a reduction in these key biomarkers means is promising since these cytokines all play vital roles in the onset, development and progression of multiple neuroinflammatory diseases and autoimmune disorders. We look forward to translating the in vitro results with our upcoming human studies; better clinical outcomes with less side effects would be welcomed for the treatment of diseases associated with immune inflammation.”